Refludan Coronary Syndrome Use Not Supported By Heparin-Placebo Data
Executive Summary
Aventis was unable to convince FDA and its Cardiovascular & Renal Drugs Advisory Committee that its thrombin inhibitor Refludan is superior to placebo in the treatment of acute coronary syndromes by inference from historical data comparing heparin and placebo.
You may also be interested in...
Aventis Retains Revasc; Refludan Divestment Ordered By FTC
Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.
Aventis Retains Revasc; Refludan Divestment Ordered By FTC
Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.
Aventis Refludan
Lepirudan (rDNA) for injection receives FDA "non-approvable" letter May 11 for treatment of anticoagulation in patients with acute coronary syndrome. The supplemental application was turned down by an FDA advisory committee May 2 (1"The Pink Sheet" May 8, p. 29). There are no ongoing or planned Refludan trials at this time, Aventis said